Verastem: Outlook Post DUO Results

While shares of Verastem (NASDAQ:VSTM) have tripled over the past year, looking at the three-year period, they are still in the red by around 40%.

ChartVSTM data by YCharts

On September 6th, the company announced positive top-line results from its pivotal DUO trial (n=319) examining in relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. The study evaluated its drug candidate duvelisib, a first-in-class oral dual inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma.


It's on us. Share your news here.

Submit your stories and articles to citybizlist today.